Navigation Links
Official Signing Ceremony for WIBP Strategic Alliance

MONTREAL, June 5 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that the official signing ceremony for the strategic alliance concluded earlier this year with the Wuhan Institute of Biological Products ("WIBP") a subsidiary of China National Biotec Group ("CNBG") was held on Wednesday, June 4, 2008 at CNBG's Beijing location.

Present at the signing were CNBG's President and Chief Executive Officer Ms. Lifeng Wang, WIBP's Director Dr. Xiaoming Yang, ProMetic's President and Chief Executive Officer Mr. Pierre Laurin as well as several officials from the CNBG and WIBP organizations. Additional information is available on CNBG's web site at and on WIBP's web site at

More about Wuhan Institute of Biological Products

WIBP ( or, located in Wuhan, China. is one of the subsidiaries of CNBG, has over 50 years experience in the fields of biomedical research and product development; historically strong in R&D, WIBP is the only institute certified by state to offer doctoral program among six Institute of Biological Products in CNBG. Today, WIBP has more than 1,000 employees, and major products include two dozen vaccines and plasma derivatives currently marketed throughout the China.

More about China National Biotec Group

CNBG ( or, headquartered in Beijing, China, is a state-owned enterprise and the largest biotech company in China dedicated to discover, develop, manufacture and market a broad range of human health products, including vaccines, blood derivatives, biopharmaceuticals, diagnostic reagents and others. With more than 9,000 employees and revenues of 421 million USD in 2006, CNBG is the largest producer of vaccines and blood derivatives in China, enjoying more than 80% and 30% market share respectively. The company consists of 6 Institute of Biological Products and an international trading company.

About ProMetic Life Sciences Inc.

ProMetic ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

SOURCE ProMetic Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
2. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
3. WaferGen Announces Signing of Two Private Placements
4. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
5. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
6. CTDC Attends the Inauguration Ceremony of Thin Film A-Si Manufacturing Line in Changzhou, China
7. CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line
8. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
9. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... Global Stem Cells Group announced the ... in the cities of Arica and Iquique in northern Chile. The facilities are part of ... the most advanced protocols and techniques in stem cell medicine to patients from around the ...
(Date:11/30/2015)... Mass. , Nov. 30, 2015 ... HART ), a biotechnology company developing bioengineered organ ... received written notification from The NASDAQ Stock Market ... bid price requirements. The letter noted that as ... HART,s common stock having exceeded $1.00 per share ...
(Date:11/30/2015)... Nov. 30, 2015 Human Longevity, Inc. (HLI), ... has acquired Cypher Genomics, Inc., a leading genome informatics ... interpretation software solutions. The San Diego ... including Cypher CEO and Co-founder, Ashley Van Zeeland , ... Business.  Financial details of the deal were not disclosed. ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, ... in Vienna, Austria to be ... owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced ... Therapy Suite at the 3rd European Congress of NeuroRehabilitation ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
Breaking Biology News(10 mins):